New Drug Cuts Heart Attack & Stroke Risk in Diabetes, Kidney & Heart Failure Patients
- sotagliflozin, a medication recently approved by the Food and Drug Management for treating type 2 diabetes and kidney disease in individuals with cardiovascular risk factors, has demonstrated a...
- The drug functions as a sodium-glucose cotransporter (SGLT) inhibitor, targeting both SGLT1 and SGLT2 proteins responsible for glucose and sodium movement across cell membranes, thus regulating blood sugar.
- the study, published in The Lancet Diabetes & Endocrinology, marks the first instance of an SGLT inhibitor exhibiting such distinct cardiovascular advantages.
Sotagliflozin, a newly approved drug, dramatically reduces teh risk of heart attacks and strokes in patients with type 2 diabetes, kidney disease, and existing cardiovascular issues. This groundbreaking medication, a sodium-glucose cotransporter (SGLT) inhibitor targeting both SGLT1 and SGLT2 proteins, showed a meaningful 23% reduction in cardiovascular events during clinical trials. Unlike other SGLT2 inhibitors, its dual action offers unique advantages. The SCORED trial, involving over 10,000 patients, revealed sotagliflozin’s effectiveness in mitigating life-threatening risks, offering physicians a powerful new tool. News directory 3 is tracking this medical advancement. Explore the long-term implications of this treatment. Discover what’s next …
Sotagliflozin Reduces Heart Attack and stroke Risk in High-Risk Patients
Updated June 09, 2025
sotagliflozin, a medication recently approved by the Food and Drug Management for treating type 2 diabetes and kidney disease in individuals with cardiovascular risk factors, has demonstrated a significant reduction in the occurrence of heart attacks and strokes. Thes findings come from an international clinical trial spearheaded by a Mount Sinai researcher.
The drug functions as a sodium-glucose cotransporter (SGLT) inhibitor, targeting both SGLT1 and SGLT2 proteins responsible for glucose and sodium movement across cell membranes, thus regulating blood sugar. Sotagliflozin’s dual-action sets it apart from othre SGLT2 inhibitors.
the study, published in The Lancet Diabetes & Endocrinology, marks the first instance of an SGLT inhibitor exhibiting such distinct cardiovascular advantages. The results suggest sotagliflozin could gain broader acceptance in mitigating potentially fatal cardiovascular events on a global scale.
Dr. Deepak L.Bhatt, Director of Mount Sinai Fuster Heart Hospital, said the study highlights a novel mechanism. The combined SGLT1 and SGLT2 blockade reduces heart attack and stroke risk. He added that the benefits differ from those of other SGLT2 inhibitors used for diabetes, heart failure, and kidney disease.
The SCORED trial, a randomized, multicenter study, assessed sotagliflozin’s ability to lower life-threatening cardiovascular risks. The trial involved 10,584 patients with chronic kidney disease, type 2 diabetes, and additional cardiovascular risk factors. Participants were randomly assigned to receive either sotagliflozin or a placebo and were monitored for an average of 16 months. the sotagliflozin group experienced a 23% decrease in heart attacks, strokes, and cardiovascular-related deaths compared to the placebo group.
According to Dr. Bhatt, physicians now have a new option to reduce global cardiovascular risk. The drug’s approval already covers reducing deaths from cardiovascular causes, hospitalizations for heart failure, and urgent heart failure visits in high-risk patients. The new data further supports it’s potential for wider use by showing it reduces the risk of heart attacks and strokes.
Lexicon Pharmaceuticals provided funding for the trial. The Icahn School of Medicine at Mount sinai receives research funding from Lexicon Pharmaceuticals related to Dr. Bhatt’s role as Chair of the SCORED trial.
What’s next
Further research may explore the long-term effects of sotagliflozin and its potential benefits for a broader range of patients with cardiovascular risks.